Craft

Alcon

Stock Price

CHF82.2

2024-10-29

Market Capitalization

CHF40.5 B

2024-10-29

Revenue

$10.4 B

FY, 2025

Alcon Summary

Company Summary

Overview
Alcon is a company that manufactures surgical and vision care products. It offers eye drops and gels, meibomian gland dysfunction (MGD) treatment systems, advanced technology intraocular lenses (ATIOLs), viscoelastic, ophthalmic microscopes, etc.
Type
Public
Status
Active
Founded
1945
HQ
Geneva, CH | view all locations
Website
https://www.alcon.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David Endicott

    David Endicott, Chief Executive Officer & Director

  • Ian Bell

    Ian Bell, President, Global Business & Innovation

  • Rajkumar Narayanan

    Rajkumar Narayanan, President, International

  • Andrew Pawson

    Andrew Pawson, President & GM Global Vision Care Franchise, President & GM, Global Vision Care Franchise

Operating MetricsView all

Countries

60

Sep, 2022

Countries (Customers)

140

Sep, 2022

Business Areas

2

Sep, 2022

LocationsView all

29 locations detected

  • Geneva, GE HQ

    Switzerland

    Chemin de Blandonnet 8

  • Fort Worth, TX

    United States

    6201 South Fwy

  • Macquarie Park, NSW

    Australia

    Suite 1, Level 7/15 Talavera Rd

  • Wien, Wien

    Austria

    Am Tabor 44/OG/Top 3. 05

  • Mechelen, Vlaanderen

    Belgium

    Building Elephantus, Stationsstraat 55

  • Mississauga, ON

    Canada

    2665 Meadowpine Blvd

and 23 others

Alcon Financials

Summary Financials

Revenue (FY, 2025)
$10.4B
Gross profit (FY, 2025)
$7.2B
Net income (FY, 2025)
$980.0M
Cash (FY, 2025)
$1.5B
EBIT (FY, 2025)
$1.3B
Enterprise value
$44.3B

Footer menu